Amgen Inc. (NASDAQ:AMGN) reported its Q4 results, with total revenue of $6.85 billion (up 3% year-over-year) coming in slightly below the consensus estimate of $6.87 billion, and adjusted EPS of $4.36 beating the consensus estimate of $4.04.

The company provided promising long-term financial guidance featuring mid-single-digit revenue CAGR. The company expects 2022 EPS in the range of $17.00–18.00, compared to the consensus estimate of $17.67.

According to the analysts, the company’s 2022 guidance was more conservative while the company delivered reasonable Q4/21 financial results, demonstrating consistent execution despite the continued pandemic impact.